Kala Bio, INC. (KALA) SEC Filings — 2024

Filings

• Kala Bio Files 8-K: Material Agreement, Equity Sales, Bylaw Changes — 8-K · Dec 30, 2024
• Kala Bio, INC. SC 13G Filing — SC 13G · Nov 14, 2024
• Kala Bio Q3 2024: $275.9M Assets, $4.6M Cash — 10-Q · Nov 12, 2024
• Kala Bio Announces CMO Departure, New Directors — 8-K · Sep 25, 2024
• Kala Bio Q2 2024: Assets $276M, Liabilities $4.6M — 10-Q · Aug 6, 2024
• SR One Capital Management Discloses Stake in Kala Bio — SC 13D · Jul 8, 2024
• Baker Bros. Advisors reports 17.1% stake in KALA BIO, Inc. — SC 13D · Jun 28, 2024
• Kala Bio Announces Material Agreement and Equity Transactions — 8-K · Jun 27, 2024
• KALA BIO Files 8-K on Shareholder Vote Matters — 8-K · Jun 12, 2024
• KALA BIO Proxy Statement Filed — DEFA14A · May 30, 2024
• Kala Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
• Kala Bio Files Proxy Materials — DEFA14A · Apr 29, 2024
• KALA BIO, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024
• KALA BIO, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 26, 2024
• Bausch + Lomb to Acquire KALA BIO, Inc. — 8-K · Mar 4, 2024
• Kala Bio, INC. SC 13G Filing — SC 13G · Feb 16, 2024
• Kala Bio, INC. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Kala Bio, INC. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Millennium Management Reduces KALA BIO Stake as of Dec 31, 2023 — SC 13G/A · Jan 29, 2024